Table 1 Patient and transplantation characteristics

From: Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation

  All patients ATG <6 mg/kg ATG ≥6 mg/kg p value
  N % N % N %  
N 234   195   39   
Age, median (range) 55 (22–70) 56 (22–70) 55 (39–65) 0.976
Transplantation period
 2000–2008 122 52% 95 48% 27 69% 0.022
 2009–2013 112 48% 100 51% 12 31%  
Time from diagnosis to Allo-HSCT
 ≤ 6 Months 138 59% 118 60% 20 51% 0.291
 > 6 Months 96 41% 77 39% 19 49%  
Conditioning regimens
 Flu-Bu 214 91% 182 93% 32 82% 0.052
 Other 20 9% 13 7% 7 18%  
Adverse cytogenetics
 No 193 82% 161 82% 32 82% 0.939
 Yes 41 18% 34 17% 7 18%  
Follow up, median (range) 38 (2–143) 37 (2–143) 41 (5–123) 0.403
  1. Bu busulfan, Flu fludarabine